Cargando…

Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma

Avelumab, an anti–programmed death‐ligand 1 monoclonal antibody approved for the treatment of metastatic Merkel cell carcinoma and platinum‐treated urothelial carcinoma, was initially approved with a 10 mg/kg weight‐based dose. We report pharmacokinetic (PK)/pharmacodynamic analyses for avelumab com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novakovic, Ana M., Wilkins, Justin J., Dai, Haiqing, Wade, Janet R., Neuteboom, Berend, Brar, Satjit, Bello, Carlo L., Girard, Pascal, Khandelwal, Akash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027979/ https://www.ncbi.nlm.nih.gov/pubmed/31553054 http://dx.doi.org/10.1002/cpt.1645

Ejemplares similares

Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma
por: Wilkins, Justin J., et al.
Publicado: (2019)

Model‐informed drug development supporting the approval of the avelumab flat‐dose regimen in patients with advanced renal cell carcinoma
por: Masters, Joanna C., et al.
Publicado: (2022)

Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
por: Grisic, Ana-Marija, et al.
Publicado: (2022)

Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors
por: Vugmeyster, Yulia, et al.
Publicado: (2022)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

Avelumab-induced Pneumonitis in Metastatic Merkel Cell Carcinoma
por: Morimoto, Toshiki, et al.
Publicado: (2022)

Immunotherapy in Merkel cell carcinoma: role of Avelumab
por: Palla, Amruth R, et al.
Publicado: (2018)

Re-Induction of Avelumab for Patients with Metastatic Merkel Cell Carcinoma
por: Hiroyuki, Goto, et al.
Publicado: (2023)

Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
por: Lanitis, Tereza, et al.
Publicado: (2019)

Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
por: Bharmal, Murtuza, et al.
Publicado: (2019)

Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma
por: Tun Min, Sandy, et al.
Publicado: (2019)

A cost‐utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan
por: Chang, Wen‐Cheng, et al.
Publicado: (2021)

Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab
por: Terranova, Nadia, et al.
Publicado: (2022)

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
por: Glutsch, Valerie, et al.
Publicado: (2021)

Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma
por: Buonerba, Luciana, et al.
Publicado: (2020)

Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort
por: Levy, Sonja, et al.
Publicado: (2020)

Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program
por: Grignani, Giovanni, et al.
Publicado: (2021)

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
por: D’Angelo, Sandra P., et al.
Publicado: (2019)

Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe
por: Fife, Kate, et al.
Publicado: (2021)

Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma—A multicenter real‐world experience in Israel
por: Averbuch, Itamar, et al.
Publicado: (2023)

Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up
por: D'Angelo, S.P., et al.
Publicado: (2021)

Long-term response to avelumab and management of oligoprogression in Merkel cell carcinoma: A case report
por: Leão, Inês, et al.
Publicado: (2021)

Avelumab for Advanced Merkel Cell Carcinoma: Global Real-World Data on Patient Response and Survival
por: Lohray, Rishabh, et al.
Publicado: (2023)

Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial
por: Lambert, Jérémy, et al.
Publicado: (2020)

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
por: D'Angelo, Sandra P, et al.
Publicado: (2021)

Evaluation of the potential for QTc prolongation with avelumab
por: Vugmeyster, Yulia, et al.
Publicado: (2019)

Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab
por: Bharmal, Murtuza, et al.
Publicado: (2020)

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
por: D'Angelo, Sandra P, et al.
Publicado: (2020)

The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape
por: Koshkin, Vadim S., et al.
Publicado: (2019)

Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
por: Walker, John W, et al.
Publicado: (2020)

Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East
por: Ascierto, Paolo Antonio, et al.
Publicado: (2021)

Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination
por: Masucci, Chiara, et al.
Publicado: (2023)

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
por: Kaufman, Howard L., et al.
Publicado: (2018)

Favorable Response to Treatment with Avelumab in an HIV-Positive Patient with Advanced Merkel Cell Carcinoma Previously Refractory to Chemotherapy
por: Al Homsi, Mohammed U., et al.
Publicado: (2018)

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab
por: Incorvaia, Lorena, et al.
Publicado: (2023)

Correction: Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
Publicado: (2020)

Introducing Radiotherapy in Metastatic Merkel Cell Carcinoma Patients with Limited Progression on Avelumab: An Effective Step against Primary and Secondary Immune Resistance?
por: Ferini, Gianluca, et al.
Publicado: (2023)

Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes
por: Ten Eyck, Jennifer E, et al.
Publicado: (2022)

Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study
por: Drusbosky, Leylah, et al.
Publicado: (2020)

Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding
por: Jin, Hulin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q083c1j6db9icfttnicikqkuar